Macular Edema

16
Pipeline Programs
9
Companies
11
Clinical Trials
1 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
5
0
4
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4100%
+ 9 programs with unclassified modality

On Market (3)

Approved therapies currently available

Regeneron
EYLEAApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2011
Regeneron
EYLEA HDApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2023
Roche
VABYSMOApproved
faricimab
Roche
intravitreal2022

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
2 programs
1
1
RanibizumabPhase 4Monoclonal Antibody1 trial
Intravitreal injection of ranibizumab .3 dosePhase 1/21 trial
Active Trials
NCT00407355Completed40Est. Feb 2013
NCT01277302Completed202Est. Oct 2012
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
1
AfliberceptPhase 3
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
1
FaricimabPhase 3Monoclonal Antibody
CP
Chugai PharmaJapan - Tokyo
2 programs
2
FaricimabPhase 3Monoclonal Antibody1 trial
FaricimabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04740931Completed729Est. Jul 2023
NCT04740905Completed553Est. Jun 2023
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
2
BI 1026706Phase 21 trial
BI 1815368Phase 21 trial
Active Trials
NCT02732951Completed105Est. Oct 2017
NCT06962839Recruiting300Est. Sep 2027
ANI Pharmaceuticals
1 program
1
Fluocinolone AcetonidePhase 21 trial
Active Trials
NCT00770770Terminated
Alcon
AlconFORT WORTH, TX
1 program
1
Nepafenac ophthalmic suspension, 0.1%Phase 21 trial
Active Trials
NCT00782717Completed263Est. Jul 2010
M&
Merck & Co.RAHWAY, NJ
1 program
1
triamcinolone acetonidePhase 21 trial
Active Trials
NCT00692614Terminated2Est. Nov 2008
Novartis
NovartisBASEL, Switzerland
2 programs
2
LKA651Phase 11 trial
MHU650Phase 11 trial
Active Trials
NCT02867735Completed28Est. Feb 2018
NCT04635800Completed21Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
GenentechRanibizumab
Chugai PharmaFaricimab
Chugai PharmaFaricimab
Boehringer IngelheimBI 1815368
Boehringer IngelheimBI 1026706
ANI PharmaceuticalsFluocinolone Acetonide
AlconNepafenac ophthalmic suspension, 0.1%
Merck & Co.triamcinolone acetonide
GenentechIntravitreal injection of ranibizumab .3 dose
NovartisMHU650
NovartisLKA651

Clinical Trials (11)

Total enrollment: 2,243 patients across 11 trials

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

Start: Feb 2011Est. completion: Oct 2012202 patients
Phase 4Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

Start: Mar 2021Est. completion: Jun 2023553 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

Start: Mar 2021Est. completion: Jul 2023729 patients
Phase 3Completed

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

Start: Jun 2025Est. completion: Sep 2027300 patients
Phase 2Recruiting

Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema

Start: Apr 2016Est. completion: Oct 2017105 patients
Phase 2Completed
NCT00770770ANI PharmaceuticalsFluocinolone Acetonide

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

Start: May 2009
Phase 2Terminated
NCT00782717AlconNepafenac ophthalmic suspension, 0.1%

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

Start: Nov 2008Est. completion: Jul 2010263 patients
Phase 2Completed
NCT00692614Merck & Co.triamcinolone acetonide

A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)

Start: Jun 2008Est. completion: Nov 20082 patients
Phase 2Terminated
NCT00407355GenentechIntravitreal injection of ranibizumab .3 dose

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

Start: Jan 2006Est. completion: Feb 201340 patients
Phase 1/2Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Start: Dec 2020Est. completion: May 202221 patients
Phase 1Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

Start: Sep 2016Est. completion: Feb 201828 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 2,243 patients
9 companies competing in this space